Maurie Markman - Concepedia

Author

Maurie Markman

The University of Texas MD Anderson Cancer Center

Also Known As

M Markman, M. MARKMAN, M. Markman, MAURIE MARKMAN, Markman, Maurie, Maurie Markman

196

Publications

2.2K

Citations

H-Index

Concepts

All Affiliations

The University of Texas MD Anderson Cancer Center University of California San Diego Cleveland Clinic Eastern Regional Medical Center Cancer Treatment Centers of America

About

Maurie Markman is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, oncology, and cancer research.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	18	26	1K
2	Education	1	1	34
3	Engineering	1	1	64
4	Health Sciences	1	1	87
5	Nursing	1	1	10

Maurie Markman

Publications

1.5K

Citations

H-Index

Page 1

	Year	Citations
Tamoxifen in Platinum-Refractory Ovarian Cancer: A Gynecologic Oncology Group Ancillary Report Maurie Markman, Karen Iseminger, Kenneth D. Hatch, Gynecologic Oncology	1996	159
High-dose cisplatin with sodium thiosulfate protection. C E Pfeifle, Stephen B. Howell, R D Felthouse, Journal of Clinical Oncology Sodium Thiosulfate ProtectionHigher Cisplatin DoseMedicinal ChemistryUrologyMedicine	1985	152
Phase I Oncology Studies: Evidence That in the Era of Targeted Therapies Patients on Lower Doses Do Not Fare Worse Rajul K. Jain, J. Jack Lee, David S. Hong, Clinical Cancer Research	2010	132
Impact of the Cost of Cancer Treatment: An Internet-Based Survey Maurie Markman, Ryan Luce Journal of Oncology Practice	2010	98
Clinical Cancer Advances 2007: Major Research Advances in Cancer Treatment, Prevention, and Screening—A Report From the American Society of Clinical Oncology Julie R. Gralow, Robert F. Ozols, Dean F. Bajorin, Journal of Clinical Oncology Cancer ManagementPathologyAmerican SocietyBreast Cancer IncidenceCancer Registration	2007	87
Phase I/pharmacokinetic study of intraperitoneal cisplatin and etoposide. Solomon Zimm, Stephen Cleary, William E. Lucas, PubMed Phase I/pharmacokinetic StudyEtoposide ExposurePeritoneal DialysisMedicinePharmacology	1987	83
Pegylated liposomal doxorubicin in the treatment of cancers of the breast and ovary Maurie Markman Expert Opinion on Pharmacotherapy Metastatic Breast CancerOncologyPhase IiBreast OncologyMedicine	2006	80
Anti-peptide antibodies detect oncogene-related proteins in urine. Henry Niman, Alastair M. Thompson, Alice L. Yu, Proceedings of the National Academy of Sciences Immunocytochemical TechniqueImmunologyGynecologyPathologyPeptide Science	1985	75
A phase I study of intraperitoneal nanoparticulate paclitaxel (Nanotax®) in patients with peritoneal malignancies Stephen K. Williamson, Gary A. Johnson, Holly Maulhardt, Cancer Chemotherapy and Pharmacology NanoparticlesNanomedicineIntraperitoneal Nanoparticulate PaclitaxelEngineeringTherapeutic Nanomaterials	2015	64
Nephrotoxicity of high-dose intracavitary cisplatin with intravenous thiosulfate protection Maurie Markman, Stephen Cleary, Stephen B. Howell European Journal of Cancer and Clinical Oncology UrologyMedicineIntravenous Thiosulfate ProtectionPharmacotherapyAcute Kidney Injury	1985	51

Page 1